Perfluoroalkyl acids (PFAAs) are organic fluorochemicals in which carbon-hydrogen bonds are replaced by carbon-fluorine bonds, with the exception of a few terminal carboxyl groups. Fully fluorinated hydrocarbons are stable at high temperatures, nonflammable, and not readily degraded or metabolized. The chemical composition of PFAAs renders this class of compounds stable and persistent in humans, wildlife, and the environment Kannan, 2001, 2002; Grasty et al., 2003; Hansen et al., 2001; Kannan et al., 2001a,b; Lau et al., 2004; Taves, 1968) . Perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) are prominent representatives of the PFAAs and have a broad industrial and consumer application for use in surfactants, coating on fabrics, upholstery and carpets, paper products used for food preservation, fire-fighting foams, and pesticides Renner, 2001 ). The estimated half-lives in humans are 3.8 years for PFOA and 5.4 years for PFOS. Both compounds are readily absorbed and poorly eliminated in humans and wildlife, and have been shown to activate peroxisome proliferatoractivated receptors (PPARs) (Ehresman et al., 2005; Grasty et al., 2003; Lau et al., 2006; Maloney and Waxman, 1999; Shipley et al., 2004) . The activation of PPARs by PFOA and PFOS is known to alter enzyme activities and effect changes in gene expression (PFOA: Kennedy et al., 2004; PFOS: Intrasuksri et al., 1998; Shipley et al., 2004) .
PFOA and PFOS in rats and mice showed developmental toxicity and other adverse effects in vivo. These effects included reduction of fetal weight, cleft palate, anasarca, delayed ossification of bones, and cardiac abnormalities, as well as, decreased neonatal survival following in utero exposure, reduction in mean post natal body weight, and a significant delay in sexual maturation Case et al., 2001; Christian et al., 1999; Gortner, 1980; Grasty et al., 2003; Kennedy et al., 2004; Peraza et al., 2006; Starkov and Wallace, 2002; Thibodeaux et al., 2003; Wetzel, 1983; Yang et al., 2002) . The wide distribution of PFAAs in the environment, their persistence in humans and wildlife, and the accumulating evidence of developmental toxicity have drawn considerable attention from the public and regulatory agencies (Ehresman et al., 2005; Maloney and Waxman, 1999; Shipley et al., 2004; U.S. Environmental Protection Agency, 2003) .
PPARs are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors. These transcription factors alter target gene expression in response to endogenous and exogenous ligands and are associated with lipid metabolism, energy homeostasis, and cell differentiation (Escher and Wahli, 2000; Hihi et al., 2002; Shipley et al., 2004) . PPARs are similar to the classical steroid, thyroid, and retinoid hormone receptors in regards to ligand modulation (Escher and Wahli, 2000; Keller and Wahli, 1997; Mangelsdorf et al., 1995; Peraza et al., 2006) . The three PPAR isoforms, PPARa, b/d, and c, are encoded by separate genes, are expressed in various tissues, and have specific roles during development and in the adult. PPAR isoforms are found in all mammals, amphibians, and teleosts examined to date (Escher and Wahli, 2000; Keller et al., 2000; Peraza et al., 2006; Peters et al., 2005; Wahli, 2002) . In mammals, PPARa plays a role in lipid homeostasis, inflammation, and peroxisome proliferation and is well expressed in the liver, heart, kidney, skeletal muscle, intestine, pancreas, lung, placenta, and adipose tissue (Auboeuf et al., 1997; Berry et al., 2003; Escher and Wahli, 2000; Hihi et al., 2002; Mukherjee et al., 1997; Sugden and Holness, 2004) . PPARb/d has a role in reverse cholesterol transport, wound healing, and cell proliferation and apoptosis and has been shown to be ubiquitously expressed in both humans and rodents with an important role during development (Berry et al., 2003; Braissant and Wahli, 1998; Braissant et al., 1996; Hihi et al., 2002; Kim et al., 2006; Lim et al., 1999; Peraza et al., 2006; Rodie et al., 2005) . PPARc plays a role in lipid storage, adipocyte differentiation, and control of inflammation and is abundantly expressed in adipose tissue, placenta, skeletal muscle, liver, heart, and bone marrow stromal cells (Asami-Miyagishi et al., 2004; Auboeuf et al., 1997; Berry et al., 2003; Escher and Wahli, 2000; Hihi et al., 2002; Mukherjee et al., 1997; Rodie et al., 2005; Tarrade et al., 2001; Vidal-Puig et al., 1997) . PPAR isoforms play a role in implantation of the embryo, maintaining pregnancy, growth and development of the fetus, and initiation of labor at term and have specific expression patterns during development in the uterus, embryo, placenta, and extra-embryonic membranes (i.e., amnion and yolk sac) (Asami-Miyagishi et al., 2004; Berry et al., 2003; Braissant and Wahli, 1998; Ding et al., 2003a,b; Dunn-Albanese et al., 2004; Komar and Curry, 2002; Peraza et al., 2006; Tarrade et al., 2001) .
Several studies have shown significant activation of the PPAR isoforms by PFAAs in Cos-1 and 3T3-L1 cells using various binding and reporter constructs in cell-based assays (Bility et al., 2004; Maloney and Waxman, 1999; Shipley et al., 2004; Vanden Heuvel et al., 2006) . The purpose of our study was to evaluate the potential for PFAAs to activate specific mouse and human PPARa, b/d, c isoforms and to determine the effect of specific PPAR antagonists on that activation.
MATERIAL AND METHODS
Chemicals. PFOS (potassium salt; > 98% pure) and PFOA (ammonium salt; > 98% pure) were purchased from Fluka Chemical (Steinheim, Switzerland). WY-14643 (4-chloro-6-(2,3-xylidine)-pyrimidinylthio acetic acid), 14 -prostaglandin J2), L-165,041, Troglitazone, GW9662, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St Louis, MO). WY-14643 and L165,041 were dissolved in DMSO to give a 25mM stock solution. Troglitazone and GW9662 were prepared as 10mM stock solutions and MK-886 was prepared as a 20mM stock solution. Dilutions were prepared in serum-free Dulbecco's Minimal Essential Medium (DMEM) and in triplicate. PFOA and PFOS were dissolved in deionized-distilled water (Picopure Hydro Services and Supplies, Inc., Durham, NC) to give a 25mM stock solution. PFOA was dissolved in water at room temperature and PFOS was dissolved in boiling water. Dilutions of PFOA and PFOS were prepared in serum-free DMEM and in triplicate to give 12 replicates for each dose concentration (i.e., n ¼ 3 independent dilutions with four replicates per dilution).
Plasmids. Mouse and human PPARa, PPARb/d, and PPARc plasmids that were used in this study are the vectors developed and described in Bility et al. (2004) and were kindly provided by Dr Jeffery M. Peters and Dr John P. Vanden Heuvel (Penn State University, PA). The ligand-binding domain of mouse or human PPARa, PPARb/d, or PPARc was fused to the DNA-binding domain of the yeast transcription factor Gal4 under the control of the SV40 promoter. This plasmid also encoded the UAS-firefly luciferase reporter under the control of the Gal4 DNA response element. The plasmids were transformed into competent DH5a bacterial cells (Gibco, Grand Island, NY) and isolated using Wizard Plus Miniprep kits (Promega, Madison, WI). Plasmid DNA was verified by AseI and DraIII restriction enzyme digestion fragment size (New England BioLabs, Inc., Ispwich, MA) via gel electrophoresis and using known agonists for each isoform to confirm activation in transfected cells.
Cell culture and transactivation assay. Cos-1 cells (ATCC, Manassas, VA) were cultured in DMEM (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS, Gibco) and 0.2 mg/ml streptomycin and 200 U/ml penicillin (Gibco) at 37°C/5% CO 2 . Cells were plated at a density of 10 4 cells per well of a 96-well plate containing 100 ll of culture medium per well. The medium was replaced with 10 ll serum-free DMEM 24 h after plating, at which time cotransfection with 1 lg/ll plasmid DNA and 0.25 ng/ll of pSEAP2-control vector (Biosciences Clontech, Palo Alto, CA) was carried out using FuGENE 6 transfection reagent (Roche Diagnostics Corp., Indianapolis, IN) following the manufacturer's recommended procedures for 96-well plates. After 3 h incubation at 37°C/5% CO 2 , 100 ll of DMEM þ FBS was added to each well and cells were maintained overnight in the culture medium. Following overnight culture, the culture medium was aspirated and replaced with serum-free DMEM containing PFOA or PFOS at concentrations of 0.5-100lM for PFOA and 1-250lM for PFOS to evaluate PPAR activation. Solutions of PFOA, PFOS, positive, and negative controls were prepared fresh on the days of treatment. The PPARa agonist, WY-14643 (10lM for mouse and human), and antagonist, MK-886 (20lM for mouse and human), were used as positive controls for the activation and antagonism of PPARa, respectively. The PPARb/d agonist, L165,041 (40lM for mouse and human), was used as a positive control for PPARb/d activation. Since a PPARb/d antagonist was not available, there is no positive control for the antagonism of mouse or human PPARb/d. Troglitazone (30lM for mouse and 3lM for human) and GW9662 (3lM for mouse and 1lM for human) were used as positive controls for PPARc as agonist and antagonist, respectively. Dose response curves for each positive control (agonists and antagonists) were determined to identify optimum concentrations to activate or inhibit mouse and human PPARa, PPARb/d, and PPARc activity.
Twenty-four hours after the treatment of the transfected Cos-1 cells with either the positive control compounds, PFOA, or PFOS, with or without the appropriate antagonist, the cells were washed once in cold phosphate-buffered saline (pH 7.4) and lysed with reporter lysis buffer (Promega) for 30 min; luciferase activity was measured using the Luciferase reporter assay kit PPAR ACTIVATION BY PFOA AND PFOS (Promega) and a LUMIstar Galaxy Luminometer (BMG Labtechnologies, Durham, NC) according to the manufacturer's recommended procedures.
Transfection and cell viability control assays. Transfection efficiency was evaluated using a SEAP concentration (secreted form of human placental alkaline phosphatase via the pSEAP2-control vector) assay. A SEAP expression control vector was transfected into cells and 24 h later, cell culture medium was collected from each well (100 ll) prior to cell washing and lysis. The concentration of SEAP was determined using the Chemiluminescent SEAP assay kit (BD Biosciences Clontech). Luciferase activity values were normalized for transfection efficiency by multiplying the measured firefly luciferase activity values by the corrected SEAP activity values obtained from the same well. Cytotoxicity assays were performed using a CellTiter-Blue cell viability assay kit (Promega) according to the fluorescence detection method. Analyses showed no cytotoxicity at the PFOA or PFOS concentrations tested.
Statistical methods. Statistical analyses were performed using Prism 4.0, GraphPad Software (San Diego, CA). Differences between treatments were determined using analysis of variance (ANOVA) followed by Dunnett's post hoc test and Bonferroni posttest, with p < 0.05 deemed significant. The fold inhibition by antagonist of normalized luciferase activity was calculated relative to agonist-treated cells, and represents the mean values ± SE based on n ¼ 3 independent dilutions, with each value being an average of duplicate determinations.
RESULTS

Positive and Negative Controls
Each of the mouse and human reporter plasmids was tested in Cos-1 cells for activation by known specific agonists and reduction of that activity by antagonists. Positive and negative controls for each mouse and human PPAR isoform are shown in Figure 1A -1F. Dose response curves for each positive control (agonists and antagonists) were determined to identify optimum concentrations to activate or inhibit mouse and human PPARa, PPARb/d, and PPARc activity. While the data for these doseresponse assays are not shown, the maximum fold induction of each agonist was as follows: mouse PPARa, 23-fold at 30lM WY-14643; human PPARa, three-fold at 50lM WY-14643; mouse PPARb/d, 30-fold at 50lM L165,041; human PPARb/d, 15-fold at 40lM L165,041; mouse PPARc, five-fold at 50lM Troglitazone; and human PPARc, four-fold at 30lM Troglitazone. The maximum percent inhibition of agonist activity by antagonist was as follows: mouse PPARa, 90% at 90lM MK-866; human PPARa, 65% at 100lM MK-866; mouse PPARc, 47% at 50lM GW9662; and human PPARc 45% at 80lM GW9662. Rather than use the maximal levels of activation or inhibition, positive control concentrations for assays of PFAA activation were selected from the mid-range of the dose response curves in order to be within scale of the PFAAs to be tested.
The positive and negative controls shown in Figure 1 are the concentrations that were run concurrently with each PFOA and PFOS experiment, and represent the average of three independent assays of the agonists and antagonists for each mouse and human construct. The mouse and human PPARa positive and negative controls are shown in Figure 1A and 1B, respectively. The mouse PPARa agonist, 10lM WY-14643, significantly activated the reporter construct (15-fold induction) and when challenged with the PPARa antagonist, MK-886 at 20lM, resulted in a significant 17% inhibition (ANOVA, p < 0.001). The human PPARa construct was not significantly activated by 10lM WY-14643 (one-fold induction) and there was no significant suppression of this activity in the presence of 20lM MK-886. For the mouse PPARb/d (Fig. 1C) , the agonist, 40lM L165,041, resulted in a significant increase in activity relative to the negative controls (28-fold induction) (ANOVA, p < 0.001). Likewise, the human PPARb/d vector (Fig. 1D) , was significantly activated by the agonist, 40lM L165,041 (13-fold induction) (ANOVA, p < 0.001). The PPARc agonist, 30lM Troglitazone, significantly stimulated the activity of the mouse PPARc construct (three-fold induction) (Fig. 1E) , and a significant 80% inhibition occurred when challenged with the antagonist, 3lM GW9662 (ANOVA, p < 0.001). The activity of the human PPARc construct (Fig. 1F ) was also significantly stimulated by the agonist, 3lM Troglitazone (two-fold induction) (ANOVA, p < 0.05), and coexposure to the antagonist, 1lM GW9662, resulted in a 23% inhibition; however, this was not a statistically significant effect. The negative controls, 0.1% DMSO, and 0.1% water did not show a significant activation or suppression of activity in any of the mouse or human PPAR isoforms, either alone or when challenged with the respective antagonists.
Activation of PPARa
Activation of mouse and human PPARa isoforms by PFOA and PFOS are shown in Figure 2 (results of 12 independent experiments). The PPARa inhibitor, MK-886, was used to challenge the activity at each concentration of PFOA and PFOS. PFOA activated mouse and human PPARa in a dosedependent manner ( Fig. 2A and 2B, respectively) . The activity of PFOA in the mouse construct ( Fig. 2A) increased with dose at 10, 20, 30, and 40lM showing a significant increase in activity compared to the negative water control (e.g., the highest significant activation was 2.5-fold at 40lM) (ANOVA, p < 0.05). At 3 and 10lM, there was a significant difference in activation between PFOA and PFOA þ MK-886 (ANOVA, p < 0.05), with 29% inhibition of activity at 3lM PFOA and 44% inhibition at 10lM PFOA. The activity of PFOA in the human PPARa construct (Fig. 2B ) also increased with dose and at 30 and 40lM showed a significant increase in activity compared to the negative water control (e.g., the highest activation was 1.88-fold at 40lM) (ANOVA, p < 0.05). At 10lM PFOA there was a significant difference between activation by PFOA and PFOA þ MK-886, with 58% inhibition (ANOVA, p < 0.05). The maximum activation achieved was observed at 40lM PFOA in both the mouse (2.3 relative light units [RLU] ) and human (1.76 RLU) PPARa constructs.
PFOS also activated the mouse PPARa construct (Fig. 2C ) with a significant increase in activity at 120lM PFOS, compared to the negative water control (e.g., highest significant activation was 1.5-fold at 120lM) (ANOVA, p < 0.01). In 110 TAKACS AND ABBOTT addition, at 60 and 120lM PFOS concentrations coexposure with MK-886 resulted in a significant 23 and 41% inhibition of activity compared with PFOS alone, respectively (ANOVA, p < 0.05). In the human PPARa construct, PFOS did not significantly increase activity (Fig. 2D ) compared to the negative water control. However, there was a significant difference in activity at 120lM between PFOS and PFOS þ MK-886, with 33% inhibition (ANOVA, p < 0.05). There was (agonist, antagonist) were dissolved in DMSO and dose concentrations were prepared in serum-free DMEM. The figures represent an average of three independent dilutions for each mouse and human construct (i.e., n ¼ 3 independent dilutions with four replicates per dilution). Cell lysates were analyzed for luciferase activity after 24 h of treatment. Significant difference between activity in cultures exposed to agonist þ antagonist is represented by a letter and asterisks represent the significant difference between the agonist activity and negative controls (DMSO, water). Abbreviations used: NC, negative control (0.1% DMSO or 0.1% water in solid bar and 0.1% DMSO or 0.1% water þ antagonist in striped bar); PC, positive control (agonist in solid bar and agonist þ antagonist in striped bar). DMSO and water, 0.1% v/v. PPAR ACTIVATION BY PFOA AND PFOS also a significant difference in activity at 250lM between PFOS and PFOS þ MK-886, however, at this concentration PFOS þ antagonist had increased activity compared to PFOS alone (ANOVA, p < 0.05). The maximum activation was observed at 120lM PFOS in both the PPARa mouse (1.50 RLU) and human (1.40 RLU) constructs.
Activation of PPARb/d
The activation of mouse and human PPARb/d by PFOA and PFOS is shown in Figure 3 (results of 12 independent experiments). There was an increase in activity across the dose range of PFOA for the mouse PPARb/d construct (Fig. 3A) , and at 40-80lM the increased activity was significant compared to the negative water control (e.g., the highest significant activation was 7.5-fold at 80lM) (ANOVA, p < 0.05). PFOA did not stimulate activity of the human PPARb/d construct (Fig. 3B) at any dose compared to the negative water control. PFOS activated mouse PPARb/d at 20 and 30lM with a significant increase in activity compared to the negative water control (e.g., the highest significant activation was 1.7-fold at 20lM) (ANOVA, p < 0.05) (Fig. 3C) . The human PPARb/d construct did not show a significant activation by PFOS at any dose when compared to the negative water control (Fig. 3D) .
Activation of PPARc
The activation of mouse and human PPARc by PFOA and PFOS is shown in Figure 4 as the results of 12 independent experiments. PFOA did not significantly increase the activity of the PPARc construct at any dose compared to the negative water control for either mouse (Fig. 4A) or human (Fig. 4B) construct. In addition, for the mouse PPARc construct (Fig.  4A) , at each concentration PFOA þ GW9662 resulted in an increased activity level over PFOA alone with 30 and 100lM concentrations showing a significant increase in activity over PFOA alone (ANOVA, p < 0.05). For the human construct PFOA þ GW9662 had similar activity compared to PFOA alone (no significant difference), except at the 50lM concentration where PFOA þ GW9662 produced a significant 58% inhibition compared to PFOA alone (Fig. 4B) . PFOS did not significantly activate the PPARc mouse or human construct at any dose compared to the negative water control (Fig. 4C and  4D , respectively). Likewise, there is no significant difference in PFOS activity when challenged with a 3lM concentration of inhibitor, GW9662, for either mouse or human construct. Table 1 provides a summary of PFOA and PFOS activation in the mouse and human PPAR constructs showing the actual RLU and providing estimates of the lowest observed effect
FIG. 2. (A-D)
The activation of mouse and human PPARa expression plasmids by PFOA (A, B, respectively) or PFOS (C, D, respectively) after transfection into Cos-1 cells. Dilutions of PFOA and PFOS were prepared in serum-free DMEM and in triplicate (i.e., n ¼ 3 independent dilutions with four replicates per dilution). The negative water control was included to show activation of nontreated cells. Cell lysates were analyzed for luciferase activity 24 h after treatment. Fold inhibition of the normalized luciferase activity was calculated relative to the agonist-treated cells. Significant difference between the agonist and antagonist is represented by a letter and asterisks represent the significant difference between the agonist activity and negative water control (ANOVA). Abbreviation used: NC, negative control (0.1% water in black bar and 0.1% water þ antagonist in white bar). Concentrations examined: PFOA, 0.5, 1, 3, 5, 10, 15, 20, 30, 40lM; PFOS, 1, 10, 20, 30, 60, 90, 120, 150, 250lM; 20lM (in mouse PPARa and human PPARa). Water, 0.1% v/v.
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TAKACS AND ABBOTT level (LOEL) values. PFOA and to a lesser extent PFOS were able to significantly activate mouse and human PPARa and this activity was inhibited by the antagonist. The mouse, but not the human, PPARb/d construct was also significantly activated by PFOA and PFOS. Neither mouse nor human PPARc constructs were activated by PFOA or PFOS.
DISCUSSION
PPARs, members of the nuclear hormone receptor superfamily, can be activated by various xenobiotics, drugs, and natural fatty acids. These transcription factors regulate genes involved in lipid metabolism, energy homeostasis, and cell differentiation (Braissant et al., 1996; Vanden Heuvel et al., 2006) . High profile PFAAs such as PFOA and PFOS have been shown to induce peroxisome proliferation, alter lipid metabolism, and exhibit developmental toxicity in laboratory animals but little is known about the mode of action in the developing embryo, fetus, or neonate. The potential toxicity of PFAAs during embryonic and neonatal development is a matter of concern and the difficulties inherent in extrapolating from laboratory animal models to the developing human make it a priority to have testing models to evaluate the ability for PFAA compounds to activate PPAR isoforms across species.
The objective of this study was to evaluate the activity of PFOA and PFOS using mouse and human PPARa, b/d, c-isoforms. The agonists and antagonists selected for this study were chosen for their selective activation or antagonism of mouse and human PPARa, b/d, c isoforms (Berger et al., 1999; Bility et al., 2004; Burgess et al., 2005; Kehrer et al., 2001; Lehmann et al., 1995; Maloney and Waxman, 1999; Peraza et al., 2006; Shipley et al., 2004; Teruel et al., 1999) . There are several known agonists and antagonists for the mouse and human PPAR isoforms; compounds that were suitable for use in culture were selected for the transfected Cos-1 cell assays. The agonist for mouse and human PPARa, WY-14643 exhibited a 15-and one-fold increase in activity over the negative controls, respectively (i.e., DMSO and water). The agonist, L165,041, for mouse and human PPARb/d exhibited a 28-and 13-fold increase in activity over the negative controls and the agonist for PPARc, Troglitazone, showed a three-and two-fold increase in activity for mouse and human PPARc over the negative controls. Our studies confirm that WY-14643, L165,041, and Troglitazone are effective agonists for mouse and human PPARa, PPARb/d, PPARc isoforms, respectively, and were particularly active with the mouse PPAR constructs. The antagonist for PPARa, MK-886, resulted in 20% inhibition of agonist activity in both mouse and human constructs in Cos-1 cells exposed to both agonist and antagonist simultaneously. Dilutions of PFOA and PFOS were prepared in serum-free DMEM and in triplicate (i.e., n ¼ 3 independent dilutions with four replicates per dilution). The negative water control was included to show activation of nontreated cells. Cell lysates were analyzed for luciferase activity 24 h after treatment. Asterisks represent the significant difference between the agonist activity and negative water control (ANOVA). Abbreviation used: NC, negative control (0.1% water in black bar). Concentrations used: PFOA, 10, 15, 20, 30, 40, 50, 60, 70, 80lM; PFOS, 10, 15, 20, 30, 40, 50, 60, 70, 80lM. Water, 0.1% v/v. PPAR ACTIVATION BY PFOA AND PFOS The PPARa antagonist, MK-886, is a noncompetitive inhibitor (Kehrer et al., 2001 ) and this may have contributed to the inconsistent suppression of WY-14643 activity in the mouse and human PPARa constructs. Another PPARa antagonist, GW6471 (Sigma), was attempted for better inhibition of WY-14643 activity in both the mouse and human constructs; however, GW6471 came out of solution at 50lM during incubation in DMEM at 37°C/5% CO 2 , and slowed cell growth substantially at that concentration (data not shown). There was no specific antagonist available for PPARb/d. The PPARc antagonist, GW9662, induced 20 and 80% inhibition of agonist activity in the human and mouse PPARc constructs, respectively.
As summarized in Table 1 , PFOA showed significant increases in activity in both mouse and human PPARa constructs across the dose response while PFOS induced only the mouse PPARa construct, however, PFOA and PFOS activities were both reduced by the PPARa antagonist. PFOA and PFOS also increased the activity of the mouse PPARb/d, but not the human PPARb/d construct. Neither PFOA nor PFOS activated the mouse or the human PPARc construct. However, there were instances of unexpected and significant increases in activity with the PPARc construct after simultaneous exposure to agonist and antagonists. It is not clear what the increased activity of PFOA or PFOS þ GW9662 versus PFOA or PFOS alone indicates in the cells transfected with PPARc, and future studies will be needed to examine this interaction. Dilutions of PFOA and PFOS were prepared in serum-free DMEM and in triplicate (i.e., n ¼ 3 independent dilutions with four replicates per dilution). The negative water control was included to show activation of nontreated cells. Cell lysates were analyzed for luciferase activity 24 h after treatment. Fold inhibition of the normalized luciferase activity was calculated relative to the agonist-treated cells. Significant difference between the agonist and antagonist is represented by a letter and asterisks represent the significant difference between the agonist activity and negative water control (ANOVA). Abbreviation used: NC, negative control (0.1% water in black bar and 0.1% water þ antagonist in white bar). Concentrations used: PFOA, 1, 5, 10, 20, 30, 40, 50, 75, 100lM; PFOS, 1, 10, 20, 30, 60, 90, 120, 150, 250lM; GW9662, 3lM (mouse PPARc) , 1lM (human PPARc). Water, 0.1% v/v. LOEC is the lowest concentration (lM) at which there was a significant difference compared to the negative control water (ANOVA, p < 0.05).
TAKACS AND ABBOTT
Our study is in agreement with the current literature examining PFOA and PFOS activity and extends the knowledge of PPARa, b/d, c activation across species. The present study confirms that PFOA can activate mouse and human PPARa and mouse PPARb/d. In vitro models in various cell types and using a variety of expression vector approaches have shown that PFOA activates PPARa in the range of 10-100lM, that the human PPARa isoform is less sensitive to PFOA than the rodent counterpart, and that mouse PPARb/d is activated by PFOA but not the human PPARb/d counterpart (Intrasuksri et al., 1998; Maloney and Waxman, 1999; Shipley et al., 2004; Vanden Heuvel et al., 2006) . Interestingly, the lack of activity for PFOA on PPARc reported in the present study is consistent with what has been reported in another lab which also used Cos-1 cells (Maloney and Waxman, 1999) but inconsistent with that reported using 3T3-L1 cells (Vanden Heuvel et al., 2006) . Vanden Heuvel et al. reported activation of mouse and human PPARc in 3T3-L1 cells at 100 and 200lM PFOA, respectively. In Cos-1 cells, we did not detect activity with mouse or human PPARc with 100lM PFOA. This suggests that there may be a cell-type dependent effect on activation of the PPARc vector.
PFOS has been shown to activate mouse and human PPARa in 3T3-L1 cells (Vanden Heuvel et al., 2006) and in Cos-1 cells (Shipley et al., 2004) , and these findings are in agreement with our results in Cos-1 cells. PFOS was also reported to activate mouse and human PPARc, but not PPARb, in 3T3-L1 cells (Vanden Heuvel et al., 2006) . However, in Cos-1 cells, we did not detect activation of mouse or human PPARc by PFOS. We did observe PFOS activation of the mouse PPARb/d construct in Cos-1 cells. Thus, the only studies to date examining PFOS activity on PPARb and PPARc vectors (Vanden Heuvel's study and ours) used different cell types and report different outcomes. This is similar to the different outcomes for PPARb/d responses to PFOA discussed previously and may reflect an influence of cell type on outcome.
The concentrations of PFOA and PFOS used in our studies were within the ranges found in maternal serum of rats and mice (0.69-199 lg/ml) (PFOS: Lau et al., 2003; Thibodeaux et al., 2003; PFOA: Lau et al., 2006) following doses that caused developmental toxicity or mortality in offspring (1lM0 .5 ppm). In vivo studies investigating the effects of PFOA during pregnancy in the rat and mouse detected full-litter resorptions and neonatal mortality as well as development toxicity, including retarded postnatal growth and significant delays in reaching sexual maturity (Lau et al., 2004 (Lau et al., , 2006 . Exposure to PFOS during pregnancy in rats resulted in cleft palate, anasarca, and heart defects, compromised postnatal survival of neonatal rats and mice, and delayed growth and development Thibodeaux et al., 2003) . Our in vitro studies clearly demonstrate that PFOA can significantly activate mouse and human PPARa and mouse PPARb/d isoforms and to a lesser extent, PFOS can activate mouse PPARa and b/d isoforms. During embryonic development, these isoforms are often coexpressed in developing tissues and organs and the relative levels vary between cell types (Braissant et al., 1996) . Inappropriate activation (i.e., increase or decrease) of one or more PPAR isoforms during critical stages of development could cause adverse developmental effects or lethality.
The PPAR transactivation model may be useful for screening other perfluorinated compounds. It is important to note several basic concepts when using this model. Activity in this model only evaluates the potential for a compound to interact with the PPAR ligand-binding domains and activate the reporter and is not necessarily predictive of the chemical's ability to produce a toxicological response in vivo. It is also possible that in an in vivo setting, PFOA and PFOS could produce biological responses that are independent of the PPAR receptors. There is also the potential in an in vitro model for endogenous ligands to be produced by the cells which could contribute to the activation of the reporters. Lastly, the use of antagonists is important because while a good correlation between compound interaction and luciferase activity is observed in transfection cell assays, this is not necessarily reflective of specific activity that would be eliminated by a competitive antagonist for the ligand-binding domain. The present work provides unique information on PPARa, b/d, and c isoform activation by using isoform-specific antagonists as a positive control to confirm the specificity of the receptor response.
In conclusion, this transactivation model has shown (1) PFOA is more capable than PFOS in activating PPARa and that the mouse PPARa is more responsive than human, (2) PFOA and PFOS activated mouse, but not human, PPARb/d, and (3) neither PFOA nor PFOS activated mouse or human PPARc reporters. It is our goal to use this model to evaluate other selected PFAAs for agonist and/or antagonist activity and to use this information to assist in selection of compounds for further testing in vivo.
